Clinical Trial Update: Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 study evaluates combination therapies for renal cell carcinoma in patients with recurrent disease during or after anti-PD-(L)1 therapy and is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING